Resumen de Neutrophil-to-lymphocyte ratio and lactate dehydrogenase as biomarkers for urothelial cancer treated with immunotherapy
G. L. Banna, Rosario Di Quattro, Lorenzo Malatino, Gema Fornasini, A. Addeo, M. Maruzzo, V. Urzia, F. Rundo, H. Lipari, U. De Giorgi, U. Basso
PurposeTo identify patients with metastatic urothelial cancer (mUC) unlikely to benefit from immune-checkpoint inhibi-tors (ICIs).Methods/PatientsWe explored the predictive and prognostic values of baseline neutrophil-to-lymphocyte ratio (NLR), with cut-offs ≥ 3 and ≥ 5, and of a urothelial immune prognostic index (UIPI, based on increased NLR and LDH), on 146 patients.Results NLR and UIPI significantly predicted progressive disease and progression-free survival with both cut-offs (p = 0.0069, p = 0.0034, p = 0.0160, p = 0.0063; p < 0.001, p = 0.021, p = 0.014, p = 0.026; for NLR-3, NLR-5, UIPI-3, UIPI-5, respectively) and overall survival when NLR cut-off was ≥ 5 (p = 0.03 and p = 0.024, for NLR-5 and UIPI-5, respectively).ConclusionsNLR-5 deserves prospective validation to identify mUC patients with poor prognosis following ICIs.
